OTLK - OTLK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead the Outlook Therapeutics Class Action Lawsuit | Benzinga
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Outlook Therapeutics class action lawsuit seeks to represent purchasers or acquirers of Outlook Therapeutics, Inc. (NASDAQ:OTLK) securities between December 29, 2022 and August 29, 2023, inclusive (the "Class Period"). Captioned Alsaidi v. Outlook Therapeutics, Inc., No. 23-cv-21862 (D.N.J.), the Outlook Therapeutics class action lawsuit charges Outlook Therapeutics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Outlook Therapeutics class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-outlook-therapeutics-inc-class-action-lawsuit-otlk.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Outlook Therapeutics' lead product candidate is ONS-5010, an ophthalmic formulation of the antibody bevacizumab for the treatment of wet age-related macular degeneration ("wet AMD") and other retina diseases.
The Outlook Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) there was a lack of substantial evidence supporting ONS-5010 as a treatment for ...